The primary use of trazodone is the treatment of major depression. Data from open and double-blind trials suggest the antidepressant efficacy of trazodone is comparable to that of amitriptyline, doxepin, and mianserin. Also, trazodone showed anxiolytic properties, low cardiotoxicity, and relatively mild side effects. The half-life of trazodone in the initial phase is about 3–6 h and the half-life in the terminal phase is about 5–9 h. TZD is extensively metabolized with only about 1% of the dose excreted unchanged in urine after 24 hr. Around 70 to 75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours.